Lifecore Biomedical
LFCR
104 hedge funds and large institutions have $288M invested in Lifecore Biomedical in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 10 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
12% more capital invested
Capital invested by funds: $258M → $288M (+$30M)
5% more funds holding
Funds holding: 99 → 104 (+5)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
3.33% less ownership
Funds ownership: 94.24% → 90.91% (-3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPAM
Legion Partners Asset Management
Los Angeles,
California
|
+$6.64M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$4.44M |
| 3 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
+$2.72M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$1.97M |
| 5 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$15.5M |
| 2 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$7.86M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$5.96M |
| 4 |
RA
Royce & Associates
New York
|
-$2.4M |
| 5 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
-$1.06M |
LFCR Hedge Fund Activity: Q3 2019 in Review
104 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2019, worth a combined $288M — up 12% from $258M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LFCR positions and 10 closed out — a net gain of 5 holders — while 34 added to existing stakes and 34 trimmed.
The largest buyer was Legion Partners Asset Management, opening a new position worth an estimated $6.64M. The largest seller was Franklin Resources, cutting an estimated $15.5M.
- 104 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2019, up from 99 in Q2 2019.
- Funds reported $288M of Lifecore Biomedical stock for Q3 2019, up 12% quarter-over-quarter.
- 15 funds opened new Lifecore Biomedical positions in Q3 2019 and 10 closed out, a net change of +5 holders.
- The largest Lifecore Biomedical buyer in Q3 2019 was Legion Partners Asset Management, an estimated $6.64M added.
- The largest Lifecore Biomedical seller in Q3 2019 was Franklin Resources, an estimated $15.5M sold.
Based on aggregated 13F filings for Q3 2019.